Healthcare Equipment and Supplies
Company Overview of Carmat SA
Carmat SA engages in the development of implantable orthotopic and biocompatible artificial heart organs for the treatment of heart failure patients. It also develops electrical power supply and remote diagnosis systems. The company was founded in 2008 and is based in Velizy Villacoublay, France.
36 avenue de l’Europe
CS 40533 - Immeuble l’Etendard
Velizy Villacoublay, 78941
Founded in 2008
Key Executives for Carmat SA
Chief Executive Officer
Total Annual Compensation: €195.4K
Compensation as of Fiscal Year 2016.
Carmat SA Key Developments
Carmat SA Appoints Wenzel Hurtak as Director of Manufacturing
Jul 6 17
Carmat SA announced the appointment of Wenzel Hurtak as Director of Manufacturing. Wenzel Hurtak is a seasoned medical device professional with a strong and broad expertise in R&D and Manufacturing. Engineering Graduate in Physics and Materials Science from the University of Groningen he has spent most of his career in Life Sciences companies such as Cordis /Johnson & Johnson where he held several management positions in Manufacturing and Process Engineering as well as Advanced R&D. In 2004, he joinedIntegra LifeSciences Corporation, a world leader in Neurosurgery and Orthopaedics, where he became Vice President of European Operations. Prior to joiningCARMAT, Wenzel Hurtak was Business Director New Products at Contract Medical International GmbH, a leader in Product Development for minimally invasive devices in cardiology and various other applications.
Carmat SA, Annual General Meeting, Apr 27, 2017
Apr 13 17
Carmat SA, Annual General Meeting, Apr 27, 2017, at 10:00 Central European Standard Time. Location: Best Hotel Western Plus Paris V lizy 1, place de l'Europe 78140 Velizy-Villacoublay France
CARMAT Announces Board Changes
Jan 25 17
CARMAT has announced that its Board of Directors has decided to co-opt Jean-Luc Lemercier and Dr. Michael Mack as independent directors, thus replacing Marcello Conviti and André-Michel Ballester, who have stood down, for the remainder of their mandates, i.e. until the conclusion of the shareholders’ meeting called to rule on the company’s 2021 annual accounts. Mr. Jean-Luc Lemercier has been the Vice-President Transcatheter Heart Valve EMEA at Edwards Lifesciences since 2008. He has over 20 years of experience and acknowledged leadership in the medical device industry. During his career, Mr. Lemercier has held a number of strategic positions in cardiology sector, notably at Johnson & Johnson Cordis (1996-2008), where he created and headed, among other activities, the Structural Heart Disease division. Michael Mack is an internationally recognized American cardiac surgeon with long standing expertise in the introduction of innovative medical devices and procedures in cardiovascular disease. He is the author of more than 500 scientific publications and has received the Presidential Citation of the American College of Cardiology and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award. He is currently the Director of the Cardiovascular Service Line for the Baylor Scott & White Health in Dallas (Texas), a Director of the American Board of Thoracic Surgery and a member of the FDA MDEpiNet Advisory Committee1.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries